GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of GlycoMimetics (NASDAQ:GLYCGet Free Report) in a research note issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

GlycoMimetics Price Performance

Shares of GLYC opened at $0.27 on Thursday. The company’s fifty day moving average price is $0.31 and its 200-day moving average price is $0.24. GlycoMimetics has a 1-year low of $0.14 and a 1-year high of $3.53.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in GlycoMimetics stock. Renaissance Technologies LLC grew its stake in GlycoMimetics, Inc. (NASDAQ:GLYCFree Report) by 483.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 826,851 shares of the biotechnology company’s stock after buying an additional 685,151 shares during the quarter. Renaissance Technologies LLC owned 1.28% of GlycoMimetics worth $233,000 as of its most recent SEC filing. Institutional investors own 75.19% of the company’s stock.

About GlycoMimetics

(Get Free Report)

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.

Further Reading

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.